Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care - The countrywide cross-sectional AUSTRO-PROFIT study.
clinical characteristics
comorbidities
metabolic risk factor targets
primary care
type 2 diabetes
type 2 diabetes care
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
03 Oct 2024
03 Oct 2024
Historique:
revised:
11
09
2024
received:
30
07
2024
accepted:
13
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
3
10
2024
Statut:
aheadofprint
Résumé
This study assessed the achievement rates of metabolic risk factor targets and their association with clinical characteristics and comorbidities among individuals with type 2 diabetes (T2D) treated in the primary care in Austria. A countrywide cross-sectional study, the AUSTRO-PROFIT, was conducted in Austria from 2021 to 2023 on 635 individuals with T2D. Metabolic risk factor targets were defined as the percentage of people achieving low-density lipoprotein cholesterol (LDL-C) <70 mg/dL (or < 55 mg/dL if cardiovascular or microvascular disease was present), glycated haemoglobin (HbA1c) <7% (53 mmol/mol) and blood pressure < 140/90 mmHg. The mean age of the participants was 65.7 ± 11.2 years; the median duration of T2D was 8 (4-14) years; and 58.7% of the participants were male. The percentages of participants achieving LDL-C, HbA1c, blood pressure and all targets were 44%, 53%, 57% and 13%, respectively. Older age, longer T2D duration, cardiovascular disease and microvascular complications were associated with suboptimal achievement of metabolic risk factor targets. The AUSTRO-PROFIT study revealed notable variations in metabolic targets achievement with respect to clinical characteristics and comorbidities. These findings underscore the importance of establishing national diabetes registries and implementing multifactorial targeted and individualized interventions to further improve the quality of T2D care in primary care settings in Austria.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Novo Nordisk Foundation Center for Basic Metabolic Research
Organisme : Roche Diagnostics
Organisme : MSD Sharp and Dohme
Organisme : Novartis Pharma
Organisme : Daiichi Sankyo Europe
Organisme : Österreichische Diabetes Gesellschaft
Organisme : Boehringer Ingelheim
Informations de copyright
© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271‐281. doi:10.1016/J.DIABRES.2018.02.023
WHO. Diabetes. Accessed February 1, 2024. https://www.who.int/news-room/fact-sheets/detail/diabetes
Austrian Diabetes Association. FACE DIABETES—Facts and Figures About Diabetes Mellitus. 2019. https://www.facediabetes.at/zahlen-und-fakten.html
Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25‐32. doi:10.1177/2047487319878371
S RKS, S K, A T et al. Diabetes mellitus, fasting glucose, and risk of cause‐specific death. N Engl J Med. 2011;364(9):829‐841. doi:10.1056/NEJMOA1008862
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10‐year follow‐up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577‐1589. doi:10.1056/NEJMOA0806470/SUPPL_FILE/NEJM_HOLMAN_1577SA1.PDF
Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab. 2018;20(6):1337‐1341. doi:10.1111/DOM.13243
Zoungas S, Chalmers J, Neal B, et al. Follow‐up of blood‐pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392‐1406. doi:10.1056/NEJMOA1407963/SUPPL_FILE/NEJMOA1407963_DISCLOSURES.PDF
Schofield JD, Liu Y, Rao‐Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. Diabetes Ther. 2016;7(2):203. doi:10.1007/S13300‐016‐0167‐X
Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta‐analysis of randomised controlled trials. Lancet. 2009;373(9677):1765‐1772. doi:10.1016/S0140‐6736(09)60697‐8
Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(39):4043‐4140. doi:10.1093/EURHEARTJ/EHAD192
Elsayed NA, Aleppo G, Aroda VR, et al. Glycemic targets: standards of care in diabetes—2023. Diabetes Care. 2023;46(Supplement_1):S97‐S110. doi:10.2337/DC23‐S006
Committee ADAPP, ElSayed NA, Aleppo G, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S179‐S218. doi:10.2337/DC24‐S010
Austrian Diabetes Association. Wiener klinische Wochenschrift. Cent Eur J Med. 2023;135(1):S1‐S330. Accessed July 9, 2024. https://www.oedg.at/pdf/OEDG-Leitlinien-2023-HighRes.pdf
Ballo P, Betti I, Barchielli A, et al. Prognostic role of N‐terminal pro‐brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender: results from the PROBE‐HF study. Clin Res Cardiol. 2016;105(5):421‐431. doi:10.1007/S00392‐015‐0937‐X
Price AH, Welsh P, Weir CJ, et al. N‐terminal pro‐brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetologia. 2014;57(12):2505‐2512. doi:10.1007/S00125‐014‐3375‐9
Scirica BM, Bhatt DL, Braunwald E, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(9):989‐998. doi:10.1001/JAMACARDIO.2016.3030
Neuhold S, Resl M, Huelsmann M, et al. Repeat measurements of glycated haemoglobin a(1c) and N‐terminal pro‐B‐type natriuretic peptide: divergent behaviour in diabetes mellitus. Eur J Clin Invest. 2011;41(12):1292‐1298. doi:10.1111/J.1365‐2362.2011.02539.X
Malachias MVB, Wijkman MO, Bertoluci MC. NT‐proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes. Diabetol Metab Syndr. 2022;14(1):1‐13. doi:10.1186/S13098‐022‐00837‐6
Flamm M, Winkler H, Panisch S, et al. Quality of diabetes care in Austrian diabetic patients willing to participate in a DMP—at baseline. Wien Klin Wochenschr. 2011;123(13‐14):436‐443. doi:10.1007/S00508‐011‐1600‐9/METRICS
Schmutterer I, Delcour J, Griebler R. Österreichischer Diabetesbericht 2017. Bundesministerium für Gesundheit und Frauen; 2017 Accessed July 3, 2024. https://jasmin.goeg.at/id/eprint/327/1/diabetesbericht2017.pdf
OECD. Austria: Country Health Profile 2023; 2023 Accessed September 23, 2024. www.oecd.org
Seidu S, Cos X, Brunton S, et al. A disease state approach to the pharmacological management of type 2 diabetes in primary care: a position statement by primary care diabetes Europe. Prim Care Diabetes. 2021;15(1):31‐51. doi:10.1016/J.PCD.2020.05.004
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453‐1457. doi:10.1016/S0140‐6736(07)61602‐X
Phillips WR, Sturgiss E, Glasziou P, et al. Improving the reporting of primary care research: consensus reporting items for studies in primary care—the CRISP statement. Ann Fam Med. 2023;21(6):549‐555. doi:10.1370/AFM.3029/‐/DC1
Bentham J, Di Cesare M, Bilano V, et al. Worldwide trends in body‐mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population‐based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627‐2642. doi:10.1016/S0140‐6736(17)32129‐3
Bayes‐Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT‐proBNP: a clinical consensus statement from the heart failure association of the ESC. Eur J Heart Fail. 2023;25(11):1891‐1898. doi:10.1002/EJHF.3036
Bakke DI, Thue G, et al. Variation in the achievement of HbA1c, blood pressure and LDL cholesterol targets in type 2 diabetes in general practice and characteristics associated with risk factor control. Diabet Med. 2020;37(9):1471‐1481. doi:10.1111/DME.14159
Alkandari A, Vaucher J, Marques‐Vidal P. Trends in glycemic, blood pressure, and lipid control in adults with diabetes in Switzerland: the CoLaus|PsyCoLaus study. BMJ Open Diabetes Res Care. 2023;11(3):e003377. doi:10.1136/BMJDRC‐2023‐003377
Ray KK, Molemans B, Marieke Schoonen W, et al. EU‐wide cross‐sectional observational study of lipid‐modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279‐1289. doi:10.1093/EURJPC/ZWAA047
Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high‐ and very high‐risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. doi:10.1016/J.LANEPE.2023.100624
American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S17‐S38. doi:10.2337/DC22‐S002
Bayram F, Sonmez A, Haymana C, et al. Utilization of statins and LDL‐cholesterol target attainment in Turkish patients with type 2 diabetes—a nationwide cross‐sectional study (TEMD dyslipidemia study). Lipids Health Dis. 2020;19(1):1‐11. doi:10.1186/S12944‐020‐01408‐2/FIGURES/4
Berteotti M, Profili F, Nreu B, et al. LDL‐cholesterol target levels achievement in high‐risk patients: an (un)expected gender bias. Nutr Metab Cardiovasc Dis. 2024;34(1):145‐152. doi:10.1016/J.NUMECD.2023.09.023
Mombelli G, Bosisio R, Calabresi L, et al. Gender‐related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. J Clin Lipidol. 2015;9(2):226‐233. doi:10.1016/J.JACL.2014.12.003
Hyun KK, Redfern J, Patel A, et al. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare. Heart. 2017;103(7):500‐506. doi:10.1136/HEARTJNL‐2016‐310216
Rachamin Y, Grischott T, Rosemann T, Meyer MR. Inferior control of low‐density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: a large‐scale, cross‐sectional study in primary care. Atherosclerosis. 2021;324:141‐147. doi:10.1016/J.ATHEROSCLEROSIS.2021.02.024
Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta‐analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431‐437. doi:10.1016/S2213‐8587(17)30104‐3
Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288‐2298. doi:10.1007/S00125‐009‐1470‐0
Monami M, Candido R, Pintaudi B, Targher G, Mannucci E. Improvement of glycemic control in type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021;31(9):2539‐2546. doi:10.1016/J.NUMECD.2021.05.010
Group TAC. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560‐2572. doi:10.1056/NEJMOA0802987/SUPPL_FILE/NEJM_ADVANCE_2560SA1.PDF
Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta‐analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19(9):604‐612. doi:10.1016/J.NUMECD.2009.03.021
Khunti K, Ceriello A, Cos X, De Block C. Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: a meta‐analysis. Diabetes Res Clin Pract. 2018;137:137‐148. doi:10.1016/J.DIABRES.2017.12.004
Vlacho B, Fernandez‐Camins B, Canudas‐Ventura A, et al. Performance of primary care physicians in the management of glycemia, lipids, and blood pressure among people with type 2 diabetes: a cross‐sectional study. J Clin Med. 2024;13(6):1544. doi:10.3390/JCM13061544/S1
Kloos C, Müller N, Hartmann P, et al. High quality of diabetes care based upon individualised treatment goals—a cross sectional study in 4784 patients in Germany. Exp Clin Endocrinol Diabetes. 2016;124(5):294‐299. doi:10.1055/S‐0035‐1569380
Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase 4 (DPP‐4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta‐analysis. BMC Pharmacol Toxicol. 2019;20(1):1‐9. doi:10.1186/S40360‐019‐0293‐Y/FIGURES/4
Kim HJ, Il KK. Blood pressure target in type 2 diabetes mellitus. Diabetes Metab J. 2022;46(5):667‐674. doi:10.4093/DMJ.2022.0215
Yang Q, Zheng R, Wang S, et al. Systolic blood pressure control targets to prevent major cardiovascular events and death in patients with type 2 diabetes: a systematic review and network meta‐analysis. Hypertension. 2023;80(8):1640‐1653. doi:10.1161/HYPERTENSIONAHA.123.20954
Boyle AJ, Shih H, Hwang J, et al. Cardiomyopathy of aging in the mammalian heart is characterized by myocardial hypertrophy, fibrosis and a predisposition towards cardiomyocyte apoptosis and autophagy. Exp Gerontol. 2011;46(7):549‐559. doi:10.1016/J.EXGER.2011.02.010
Noronha IL, Santa‐Catharina GP, Andrade L, Coelho VA, Jacob‐Filho W, Elias RM. Glomerular filtration in the aging population. Front Med (Lausanne). 2022;15:9. doi:10.3389/FMED.2022.769329
Muscari A, Bianchi G, Forti P, Magalotti D, Pandolfi P, Zoli M. N‐terminal pro B‐type natriuretic peptide (NT‐proBNP): a possible surrogate of biological age in the elderly people. Geroscience. 2021;43(2):845. doi:10.1007/S11357‐020‐00249‐2